FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Glenmark Pharmaceuticals Telmisartan and Hydrochlorothiazide Tablets Recall

Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Aug 17, 2022
Recall ID
D-1306-2022
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Telmisartan and Hydrochlorothiazide Tablets starting Jun 29, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1306-2022 on Aug 17, 2022. Reason: Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister . Status: Terminated.

Why it was recalled

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Product description

Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc,m USA, Mahwah, NJ 07430, NDC 68462-841-13.

Lot numbers, UPCs & expiration codes

Lots 17210929 & 17210930, Exp Date 05/2023; Lot 17211203, Exp Date 06/2023 & Lots 17211643, 17211646 & 17211649, Exp Date 08/2023

Where it was sold

nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1306-2022
Classification
Class II
Status
Terminated
Recall initiated
Jun 29, 2022
FDA report date
Aug 17, 2022
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-1306-2022, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Terminated
Country
United States
Event ID
90541
Address
750 Corporate Dr
Code information
Lots 17210929 & 17210930, Exp Date 05/2023; Lot 17211203, Exp Date 06/2023 & Lots 17211643, 17211646 & 17211649, Exp Date 08/2023
Postal code
07430-2009
Report date
Aug 17, 2022
Product type
Drugs
Recall number
D-1306-2022
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Termination date
Jun 27, 2024
Reason for recall
Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .
Voluntary / mandated
Voluntary: Firm initiated
Product description
Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc,m USA, Mahwah, NJ 07430, NDC 68462-841-13.
Distribution pattern
nationwide
Recall initiation date
Jun 29, 2022
Initial firm notification
Letter
Center classification date
Aug 5, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1306-2022, published Aug 17, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls